ADMINISTRATION-TIME-DEPENDENT EFFECTS OF SPIRAPRIL ON AMBULATORY BLOOD PRESSURE IN UNCOMPLICATED ESSENTIAL HYPERTENSION

REFERENCES

• Angeli A, Gatti G, Masera R. (1992). Chronobiology of the hypothalamic-pituitary-adrenal and renin-angiotensin-aldosterone systems. In Touitou Y, Haus E (eds.). Biologic rhythms in clinical and laboratory medicine. Berlin: Springer-Verlag, pp. 292–314.
   Google Scholar
• Ayala DE, Hermida RC, Chayán Mojón A, Fontao AJ, Fernández JR. (2009). Circadian pattern of ambulatory blood pressure in untreated hypertensive patients with and without metabolic syndrome. Chronobiol. Int. 26:1189–1205.
   PubMed Web of Science ®Google Scholar
• Bartter FC, Chan JCM, Simpson HW. (1979). Chronobiological aspect of plasma renin activity, plasma aldosterone and urinary electrolytes. In Krieger DT (ed.). Endocrine rhythms. New York: Raven, 49–132.
   Google Scholar
• Brotman DJ, Davidson MB, Boumitri M, Vidt DG. (2008). Impaired diurnal blood pressure variation and all-cause mortality. Am. J. Hypertens. 21:92–97.
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. (2005). Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension 46:156–161.
   PubMed Web of Science ®Google Scholar
• Duguay D, Cermakian N. (2009). The crosstalk between physiology and circadian clock proteins. Chronobiol. Int. 26:1479–1513.
   PubMed Web of Science ®Google Scholar
• Düsing R, Müller U. (2003). Blood pressure lowering by the ACE-inhibitor spirapril. 24-hour efficacy of real once daily application of spirapril (HERAS study). MMW Fortschr. Med. 145 ( Suppl. 3):77–80.
   PubMedGoogle Scholar
• Eguchi K, Kario K, Shimada K. (2002). Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens. Res. 25:329–333.
   PubMed Web of Science ®Google Scholar
• Fernández JR, Hermida RC. (1998). Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol. Int. 15:191–204.
   PubMed Web of Science ®Google Scholar
• Fernández JR, Mojón A, Hermida RC. (2004). Comparison of parameters from rhythmometric models with multiple components on hybrid data. Chronobiol. Int. 21:467–482.
   Web of Science ®Google Scholar
• Hayduk K, Kraul H. (1999). Efficacy and safety of spirapril in mild-to-moderate hypertension. J. Cardiovasc. Pharmacol. 34 ( Suppl. 1):S19–S23.
   PubMed Web of Science ®Google Scholar
• Hermida RC. (2007). Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: Rationale and design of the MAPEC study. Chronobiol. Int. 24:749–775.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. (2009). Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: Improved blood pressure control with bedtime dosing. Hypertension 54:40–46.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. (2003). Administration-time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42:283–290.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. (2007a). Chronotherapy of hypertension: Administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv. Drug Deliv. Rev. 59:923–939.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. (2007b). Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 50:715–722.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Khder Y, Calvo C. (2008). Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: A prospective, randomized, open-label, blinded end-point trial. Clin. Ther. 30:108–120.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Chayán L, Mojón A, Fernández JR. (2009). Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol. Int. 26:61–79.
   PubMed Web of Science ®Google Scholar
• Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. (2005). Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 45:240–245.
   PubMed Web of Science ®Google Scholar
• Koopman MG, Koomen GC, Krediet RT, de Moor EA, Hoek FJ, Arisz L. (1989). Circadian rhythm of glomerular filtration rate in normal individuals. Clin. Sci. (Lond.) 77:105–111.
   PubMed Web of Science ®Google Scholar
• Labrecque G, Beauchamp D. (2003). Rhythms and pharmacokinetics. In Redfern P (ed.). Chronotherapeutics. London: Pharmaceutical Press, pp. 75–110.
   Google Scholar
• Lacourcière Y, Neutel JM, Davidai G, Koval S. (2006). A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatiry blood pressure monitoring. Am. J. Hypertens. 19:104–112.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker HAJ, Zanchetti A. (2007). 2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Morgan TO. (2009). Does it matter when drugs are taken? Hypertension 54:23–24.
   PubMed Web of Science ®Google Scholar
• Neutel JM, Elliot WJ, Izzo JL, Chen CL, Masonson HN. (2002). Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J. Clin. Hypertens. 4:325–331.
   PubMedGoogle Scholar
• Nozawa M, Sugimoto K, Ohmori M, Ando H, Fujimura A. (2006). Dosing time-dependent effect of temocapril on the mortality of stroke-prone spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 316:176–181.
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. (2002). Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J. Hypertens. 20:2183–2189.
   PubMed Web of Science ®Google Scholar
• Ohmori M, Fujimura A. (2005). ACE inhibitors and chronotherapy. Clin. Exp. Hypertens. 2&3:179–185.
   Google Scholar
• Perez-Lloret S, Risk M, Golombek DA, Cardinali DP, Sanchez R, Ramirez A. (2008). Blunting of circadian rhythms and increased acrophase variability in sleep-time hypertensive subjects. Chronobiol. Int. 25:99–113.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH. (2000). Circadian rhythm and environmental determinants of blood pressure regulation in normal and hypertensive conditions. In: White WB (ed.). Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa, NJ: Humana Press, pp. 79–118.
   Google Scholar
• Portaluppi F, Touitou Y, Smolensky MH. (2008). Ethical and methodological standards for laboratory and medical biological rhythm research. Chronobiol. Int. 25:999–1016.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Cortelli P, Buonaura GC, Smolensky MH, Fabbian F. (2009). Do restless legs syndrome (RLS) and periodic limb movements of sleep (PLMS) play a role in noctural hypertension and increased cardiovascualr risk of renally impaired patients? Chronobiol. Int. 26:1206–1221.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard R, ÓBrien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, for the Systolic Hypertension in Europe (Syst-Eur) trial investigators. (1999). Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. JAMA 282:539–546.
   PubMed Web of Science ®Google Scholar
• Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. (2001). Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38:e28–e32.
   PubMed Web of Science ®Google Scholar
• Witte K, Lemmer B. (2003). Rhythms and pharmacodynamics. In Redfern P (ed.). Chronotherapeutics. London: Pharmaceutical Press, pp. 111–126.
   Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. (2000). Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:145–153.
   PubMed Web of Science ®Google Scholar